Plain-English translation of NCT06915727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called pafolacianine, which is a special fluorescent dye that lights up cancer cells during surgery. When injected into the bloodstream, pafolacianine attaches to cancer tumors and glows under special infrared imaging cameras, helping surgeons see exactly where the cancer is. The study wants to find out if this medication helps doctors identify tumors more accurately during surgical removal in children and adolescents.
Current imaging methods during cancer surgery sometimes miss small tumor spots or don't clearly show where all the cancer is located. This medication is designed to make tumors glow so surgeons can see and remove them more completely, which could improve outcomes for children with solid tumors.
You likely qualify if…
You likely don't qualify if…
You will receive the fluorescent medication (pafolacianine) through an IV over about 60 to 90 minutes before your scheduled tumor removal surgery. During your surgery, surgeons will use special infrared imaging cameras to see which areas light up, helping them identify and remove cancer tissue. Tissue samples may also be collected during surgery as part of standard care.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States